SCHEMBL24485463

SCHEMBL24485463

CCOCc1cccnc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
BRD4 O60885 1/20 0.35
MITF O75030 1/20 0.35
PDE1A P54750 2/20 0.35
PDE1B Q01064 2/20 0.35
PDE1C Q14123 2/20 0.35
GRM5 P41594 1/20 0.35
ADRA1A P35348 1/20 0.35
CD38 P28907 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
MYC P01106 1/20 0.34
TRPV1 Q8NER1 2/20 0.34
KLKB1 P03952 1/20 0.32
SSTR4 P31391 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12818788 0.80 CD38 (0.41) MAPTKDM4ECD38ALDH1A1HPGD
SCHEMBL22181623 0.77 MYC (0.39) MAPTTP53KDM4ENPC1L3MBTL1
SCHEMBL12525192 0.77 GRM5 (0.42) MAPTKDM4EPDE1APDE1BPDE1C
SCHEMBL26921312 0.76 CD38 (0.35) CD38KLKB1SSTR4TRPC5
SCHEMBL29995766 0.76 CD38 (0.35) CD38KLKB1SSTR4TRPC5
SCHEMBL21503569 0.75 KCNA5 (0.36) PDE1APDE1BPDE1CGRM5CD38
SCHEMBL28051170 0.74 CD38 (0.36) MAPTKDM4ECD38SSTR4HTT
SCHEMBL27863522 0.74 NOS3 (0.44) MAPTKDM4ENPC1L3MBTL1BRD4
SCHEMBL1810170 0.74 CYP11B1 (0.42) MAPTTP53KDM4ENPC1L3MBTL1
SCHEMBL13066846 0.73 CD38 (0.36) MAPTKDM4EL3MBTL1PDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed